Palantir Looks Like a Solid Buy, but Not Right Now
Palantir Looks Like a Solid Buy, but Not Right Now
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市場新聞、股票建議和交易提示
After reporting mixed earnings, shares of Palantir (NYSE:PLTR) are below their direct listing price. And with the company suggesting that next quarter's revenue may come in below analysts' estimates, the immediate question may be how low can the stock go? Until investors can figure that out, PLTR stock is not a buy.
在公佈喜憂參半的收益後，帕蘭提爾(紐約證券交易所：PLTR)低於其直接上市價格。鑑於該公司表示，下個季度的營收可能低於分析師的預期，眼下的問題可能是，該公司股價還能跌到多低？在投資者弄清楚這一點之前，PLTR的股票不是買入的。
However, in strictly technical terms, the sell-off is starting to look overdone. Plus, the lower the stock goes, the more it starts to look appealing from a fundamental perspective. And that means that PLTR stock looks like it will be a solid buy at some point. But with investor sentiment at all-time bearish levels, that day is not today.
然而，從嚴格的技術角度來看，拋售開始顯得有些過頭了。此外，從基本面來看，股價越低，看起來就越有吸引力。這意味着PLTR的股票看起來在某個時候將是一個堅實的買入。但在投資者情緒處於空前悲觀水平的情況下，這一天不是今天。
The more interesting question for me is what more does Palantir have to do to please investors? Upon going public, a key concern of investors was the company's reliance on its government contracts. But in its most recent earnings report, Palantir showed a 54% year-over-year (YOY) increase in sales on the commercial side of its business. Overall revenue was up 31% YOY, which was slightly ahead of analysts' expectations.
對我來説，更有趣的問題是，Palantir還需要做些什麼來取悦投資者？上市後，投資者的一個主要擔憂是該公司對政府合同的依賴。但在其最新的收益報告中，Palantir顯示其商業業務的銷售額同比增長了54%。整體營收同比增長31%，略高於分析師的預期。
Ironically, it's slower growth in the company's government-related revenue that is causing angst for investors post earnings. Palantir reported that vertical only saw a 16% YOY revenue increase. Plus the company is forecasting slower overall revenue growth for the second quarter.
具有諷刺意味的是，正是該公司與政府相關的收入增長放緩，才讓投資者在公佈業績後感到焦慮。Palantir報告稱，垂直市場的收入僅同比增長16%。此外，該公司預計第二季度整體收入增長將放緩。
- 7 Defensive Dividend Healthcare Stocks to Buy Now
- 立即買入7只防御性股息醫療保健股票
However, it's unclear whether investors are factoring in two recently announced contracts. First, the company announced a 10 million-pound ($12.5 million) contract with the U.K. Ministry of Defence. And the company also inked a 5-year, $90-million blanket purchase agreement with the Department of Health and Human Services (HHS).
不過，目前尚不清楚投資者是否在計入最近宣佈的兩份合約。首先，該公司宣佈了一份價值1000萬英鎊(1250萬美元)的合同與英國國防部合作。該公司還簽署了一份與衞生與公眾服務部(HHS)簽訂了為期5年、價值9000萬美元的一攬子採購協議。
It's fair to note that Palantir missed on earnings. And this does nothing to satisfy investors who are concerned that Palantir may find it difficult to generate meaningful earnings. The root of this concern is that the data analytics company faces too much competition to capture significantly higher market share than it already has.
值得注意的是，Palantir沒有達到預期的收益。而且，這並沒有讓投資者滿意，他們擔心Palantir可能會發現很難產生有意義的收益。這種擔憂的根源是，這家數據分析公司面臨着太多競爭，無法奪取比現有市場份額高得多的市場份額。
Still, Palantir has a consensus price target of $14.31, an 85% gain from the stock's current price. It's also over 40% lower than the consensus price target from a year ago. That's not very comforting for investors who bought PLTR stock at its 2021 highs, but it presents an intriguing opportunity for risk-tolerant investors.
儘管如此，Palantir的普遍目標價仍為14.31美元，較該股當前價格上漲了85%。這也比一年前的普遍價格目標低了40%以上。對於在2021年高點買入PLTR股票的投資者來説，這並不是很令人欣慰，但對於承受風險的投資者來説，這是一個有趣的機會。
On the date of publication, Chris Markoch did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在本文發表之日，Chris Markoch並未(直接或間接)持有本文所述證券的任何頭寸。本文表達的觀點是作者的觀點，以InvestorPlace.com為準出版指南.
The post Palantir Looks Like a Solid Buy, but Not Right Now appeared first on InvestorPlace.
Palantir的帖子看起來像是一個Solid Buy，但現在不是最先出現在InvestorPlace上的。
